Capricor Therapeutics (NASDAQ:CAPR) shares dropped after the U.S. FDA inspected its San Diego manufacturing facility for the ...

U.S. FDA successfully completed Pre-License Inspection; Company expects facility will meet all requirements to support ...

Capricor Therapeutics (CAPR) announced the completion of the Food and Drug Administration’s pre-license inspection of its San ...

Capricor Therapeutics' rating was downgraded amid FDA inspection risks, regulatory uncertainty, and potential delays in ...

Shares of Capricor Therapeutics (CAPR) were in the spotlight on Wednesday morning after the company announced the completion ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

Capricor Therapeutics has announced the appointment of Dr. Michael Binks as Chief Medical Officer, effective immediately. Dr. Binks brings 25 years of experience in clinical development and ...

For more information, or to register, please click here. Capricor plans to make its presentation available on the publications section of the Company’s website following the formal conference ...

24, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases ...

SAN DIEGO, June 11, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare ...

The FDA informed Capricor of its intent to hold the Advisory Committee meeting on July 30, 2025, although that date is pending confirmation by the FDA. At the time of the mid-cycle review ...